| 1 |
32241846 | Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. | 2021 Feb 1 |
2 |
| 2 |
33622704 | Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. | 2021 May 15 |
2 |
| 3 |
33668509 | Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma. | 2021 Feb 13 |
1 |
| 4 |
32733012 | Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. | 2020 Nov |
2 |
| 5 |
28124097 | Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. | 2017 Apr |
4 |
| 6 |
28232670 | Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. | 2017 Oct |
5 |